Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table

Ramsay, LE; Haq, Iftikhar Ul; Jackson, Paul R.; Yeo, W. W.; Pickin, D M; Payne, J. N.

doi:10.1016/s0140-6736(96)05516-x

Cited by 152 publications

(101 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some laboratories referred to national guidelines. In most cases this was appropriate, although three laboratories referred to the She⁄eld Table 17,18 that is designed to be used by clinicians before requesting lipid analysis (to show when the result may a¡ect the decision to start treatment); this might possibly have been to in£uence clinicians to restrict future requests. Fewer than 20% of laboratories provided information about treatment thresholds or targets for secondary prevention.…”

Section: Discussionmentioning

confidence: 99%

Provision of laboratory services for lipid analysis in the United Kingdom

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Provision of laboratory services for lipid analysis in the United Kingdom

et al. 2007

View full text Add to dashboard Cite

show abstract

“…5,14 Using an absolute risk as the criterion to detect and control high BP is a relatively recent development. 3 However, as with other cardiovascular risk factors (eg, hypercholesterolaemia and non-rheumatic atrial fibrillation) 15,16 measurement of absolute risk gives a realistic index of the likely benefits and risks of treatment. Prevention of cardiovascular disease is likely to require a multi-factorial approach, both in lifestyle advice and prescription of drugs.…”

Section: Discussionmentioning

confidence: 99%

Reconciling different measures of risk in the treatment of hypertension: a community-based study

Fahey

Peters

1998

J Hum Hypertens

View full text Add to dashboard Cite

Background: There is disagreement as to how cardiovascular risk in hypertensive patients should be measured. In particular, whether absolute risk measurement alone is a realistic index on which to base treatment goals. Method: A cross-sectional study on 895 treated hypertensive patients in 18 general practices in the UK. Reporting on the distribution and magnitude of agespecific absolute risk. The percentage of individuals with controlled hypertension whose absolute risk exceeds their age/sex absolute risk standard and the percentage of individuals with uncontrolled hypertension whose risk is less than their age/sex absolute risk standard. Results: Overall, 62.8% (95% CI 59.6-66%) individuals had an absolute risk that exceeded 20% over 10 years. The magnitude of absolute risk was considerable (range

show abstract

“…Hypercholesterolemia is one of the major risk factors that contributes to the development of coronary atherosclerosis (3). Recent clinical practice guidelines recommend that physicians and patients make decisions regarding coronary heart disease (CHD) prevention on assessment of underlying global CHD risk (3)(4)(5)(6)(7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Risk Evaluation of Coronary Heart Disease and Cerebrovascular Disease by the Japan Atherosclerosis Society Guidelines 2002 Using the Cohort of the Holicos-PAT Study

Koizumi

Shimizu

Miyamoto³

et al. 2005

JAT

View full text Add to dashboard Cite

Our purpose in this study was to evaluate the new JAS guidelines as a risk assessment tool in Japanese patients with hypercholesterolemia, using the cohort of the Holicos-PAT study. The Holicos-PAT study was designed as a prospective observational study. 2039 patients were followed with or without pravastatin for 5 years. We assessed coronary heart disease (CHD) and cerebrovascular disease (CVD) risks by the patient categories described in the JAS guidelines. In the Holicos-PAT study, the primary endpoints were CHD, and the secondary endpoints were CVD and total mortality. CHD event includes onset and worsening of angina pectoris, performing CABG or PTCA, non-fatal and fatal myocardial infarction, and death from CHD including heart death and sudden death. CVD events are onset or recurrence of cerebral infarction, onset of cerebral hemorrhage, and death from cerebral infarction or hemorrhage. The event rates were calculated by the person-years method, and the differences in event rates between category groups were analyzed by chi-square test. The event rates of CHD in Category A, B1, B2, B3, B4 and C, were 1.1, 4.0, 2.8, 5.7, 18.2 and 38.8 per 1,000 person-years. The rates of CHD events in the higher risk category groups, Category B4 group (p = 0.004 in whole patients) and C group (p < 0.001 in whole patients), were significantly higher than that in the combined category groups A + B1 + B2. The event rates of CVD in Category A, B1, B2, B3, B4 and C, were 2.1, 1.8, 1.8, 0.6, 10.8 and 6.4 per 1,000 person-years. The event rates of CHD in men were significantly higher than those in women, in categories B4 (p < 0.001) and C (p < 0.001). From these results, each category classified by accumulation of risk factors, showed increasing event rates of CHD and CVD. The categories in the JAS guidelines are useful to assess CHD and CVD risk in Japanese patients with hypercholesterolemia. However, the risk evaluation by the JAS guideline categories may underestimate the risk in men and overestimate it in women. J Atheroscler Thromb, 2005; 12: 48-52.

show abstract

Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table

Cited by 152 publications

References 4 publications

Provision of laboratory services for lipid analysis in the United Kingdom

Provision of laboratory services for lipid analysis in the United Kingdom

Reconciling different measures of risk in the treatment of hypertension: a community-based study

Risk Evaluation of Coronary Heart Disease and Cerebrovascular Disease by the Japan Atherosclerosis Society Guidelines 2002 Using the Cohort of the Holicos-PAT Study

Contact Info

Product

Resources

About